PCI Biotech Holding ASA (OSL:PCIB) Change In Inventory : kr0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA Change In Inventory?

PCI Biotech Holding ASA's change in inventory for the quarter that ended in Dec. 2024 was kr0.00 Mil. It means PCI Biotech Holding ASA's inventory stayed the same from Jun. 2024 to Dec. 2024 .

PCI Biotech Holding ASA's change in inventory for the fiscal year that ended in Dec. 2024 was kr0.00 Mil. It means PCI Biotech Holding ASA's inventory stayed the same from Dec. 2023 to Dec. 2024 .

PCI Biotech Holding ASA's Total Inventories for the quarter that ended in Dec. 2024 was kr0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

PCI Biotech Holding ASA Change In Inventory Historical Data

The historical data trend for PCI Biotech Holding ASA's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA Change In Inventory Chart

PCI Biotech Holding ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Inventory

Get a 7-Day Free Trial

PCI Biotech Holding ASA Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

PCI Biotech Holding ASA Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr0.00 Mil.

PCI Biotech Holding ASA (OSL:PCIB) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

PCI Biotech Holding ASA's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 2
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

PCI Biotech Holding ASA's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

PCI Biotech Holding ASA's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

PCI Biotech Holding ASA Change In Inventory Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

PCI Biotech Holding ASA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (OSL:PCIB) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

0JGL:UK

Address

Ullernchausseen 64, Oslo, NOR, N-0379

Website

https://www.pcibiotech.com

PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.

PCI Biotech Holding ASA Headlines

No Headlines